Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of linagliptin plus metformin versus linagliptin or metformin alone in type 2 diabetes
2008-001640-40Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linagliptin and metformin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Sep 2008; status: completed.
02
Drugs
linagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-001640-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001640-40.